[go: up one dir, main page]

WO2003055517A1 - Procede de correction de la reponse immunitaire et medicament - Google Patents

Procede de correction de la reponse immunitaire et medicament Download PDF

Info

Publication number
WO2003055517A1
WO2003055517A1 PCT/RU2002/000375 RU0200375W WO03055517A1 WO 2003055517 A1 WO2003055517 A1 WO 2003055517A1 RU 0200375 W RU0200375 W RU 0200375W WO 03055517 A1 WO03055517 A1 WO 03055517A1
Authority
WO
WIPO (PCT)
Prior art keywords
dilutions
complex
molecule
activated
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2002/000375
Other languages
English (en)
Russian (ru)
Inventor
Oleg Iliich Epshtein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002313938A priority Critical patent/AU2002313938A1/en
Publication of WO2003055517A1 publication Critical patent/WO2003055517A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the invention is available in the field of medicine and may be used for the treatment of medications that do not have a pronounced effect of treatment of the immune system, and
  • a preferred use of the mixture is various, preferably commercially available, homogenous dilutions.
  • the medicinal product is prepared by the following method.
  • the current processing in the process of reducing the concentration is also possible to carry out ultrasound, electric or other physical interference.
  • IDDM insulin-dependent diabetes mellitus
  • Antibodies are assigned in the form of active (potentiated) overdoses (a mixture of homeopathic dilutions C12 + C30 + C200) - at 1 table 3 times a day. After 3 days after the start of treatment, the severity of hyperglycemia decreased after food intake, after 7 days - the level of glucose at home was normalized. After 2 weeks, the doses of insulin administered were reduced by 2 times.
  • rheumatoid arthritis It is a carrier of L2L27. Acquired in connection with the disease, an updated clinical diagnosis: rheumatoid arthritis, high activity, and poliomyelitis with chronic disease.
  • ⁇ due to the intolerance of gluten-free drugs has been assigned: versatile antibodies to a synthetic drug component, Antibodies are assigned as active (potentiated) overdoses (a mixture of homeopathic dilutions C12 + C30 + C200) - ⁇ 1 tablet for absorbing all of the food 2 hours.
  • mice ⁇ yshi ⁇ y ⁇ n ⁇ y g ⁇ u ⁇ y ⁇ luchali sve ⁇ malye d ⁇ zy a ⁇ ivi ⁇ vanny ⁇ an ⁇ i ⁇ el ⁇ ⁇ m ⁇ zitsii ⁇ e ⁇ idny ⁇ ⁇ agmen ⁇ v myshiny ⁇ m ⁇ le ⁇ ul ⁇ S ⁇ lassa 1 (mixture g ⁇ me ⁇ a ⁇ iches ⁇ i ⁇ ⁇ azvedeny ⁇ 12 + C30 + ⁇ 2) - ⁇ 0.2 ml v ⁇ dn ⁇ g ⁇ ⁇ as ⁇ v ⁇ a ⁇ eg ⁇ z 2 ⁇ aza in su ⁇ i. It was shown that in the experimental group, the average life expectancy of mice was 60-80 days (in the case of 30-40 days); in mice that received activated antibodies, the weight of the number of tests and the number of tests were slightly less than in the case of control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Le procédé de traitement d'un état immuno-pathologique consiste en ce que l'on administre à un organisme des formes activées de doses extrêmement réduites d'anticorps monoclonaux ou polyclonaux, immuns ou naturels, dirigés contre la molécule du complexe d'antigène principal d'histocompatibilité (HLA) ou le complexe de la molécule HLA et du peptide qui y est associé; la forme activée est obtenue par la dilution subséquente répétée et par une action externe. Le médicament comprend une forme activée de doses extrêmement réduites d'anticorps monoclonaux ou polyclonaux, immuns ou naturels, dirigés contre la molécule du complexe d'antigène principal d'histocompatibilité (HLA) ou le complexe de la molécule HLA et du peptide qui y est associé; la forme activée est obtenue par la dilution subséquente répétée et par une action externe.
PCT/RU2002/000375 2001-12-26 2002-08-06 Procede de correction de la reponse immunitaire et medicament Ceased WO2003055517A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002313938A AU2002313938A1 (en) 2001-12-26 2002-08-06 Method for correcting immune response and medicinal agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001135014/14A RU2205025C1 (ru) 2001-12-26 2001-12-26 Способ коррекции иммунного ответа и лекарственное средство
RU2001135014 2001-12-26

Publications (1)

Publication Number Publication Date
WO2003055517A1 true WO2003055517A1 (fr) 2003-07-10

Family

ID=20254871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000375 Ceased WO2003055517A1 (fr) 2001-12-26 2002-08-06 Procede de correction de la reponse immunitaire et medicament

Country Status (3)

Country Link
AU (1) AU2002313938A1 (fr)
RU (1) RU2205025C1 (fr)
WO (1) WO2003055517A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021040570A1 (fr) * 2019-08-29 2021-03-04 Oleg Iliich Epshtein Médicament et méthode de traitement de maladies infectieuses

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
RU2535033C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
RU98109384A (ru) * 1998-05-22 2000-03-10 О.В. Чернова Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2122863C1 (ru) * 1996-09-26 1998-12-10 Институт ревматологии РАМН Способ получения иммунорегуляторного глобулина
RU2187334C2 (ru) * 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
RU98109384A (ru) * 1998-05-22 2000-03-10 О.В. Чернова Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROIT A.: "Osnovy immunologi", M., MIR, 1999, pages 305 - 307 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021040570A1 (fr) * 2019-08-29 2021-03-04 Oleg Iliich Epshtein Médicament et méthode de traitement de maladies infectieuses

Also Published As

Publication number Publication date
AU2002313938A1 (en) 2003-07-15
RU2205025C1 (ru) 2003-05-27

Similar Documents

Publication Publication Date Title
WO2003055519A1 (fr) Agent pharmaceutique et methode de traitement de maladies s'accompagnant de troubles du tonus vasculaire
WO2005000350A1 (fr) Medicament et methode de traitement d'un syndrome pathologique
US20150023972A1 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2004012764A1 (fr) Medicament et procede de traitement des maladies de la prostate
EA029400B1 (ru) Фармацевтическая композиция для лечения ожирения и сопутствующих метаболических расстройств и способ лечения
WO2004012767A1 (fr) Preparation medicinale et procede de traitement de dyserections
CN106539814A (zh) 干扰素基因刺激蛋白（sting）激动剂在抗类风湿性关节炎等疾病中的应用
RU2187334C2 (ru) Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
CA2473754C (fr) Traitement
WO2005039636A1 (fr) Produit pour potentialiser les effets curatifs et intensifier l'action d'un medicament
KR20090046970A (ko) 폴리클론항체 항-ｈｉｖ 산양 혈청의 치료제로의 용도
WO2002003910A2 (fr) Preparation antibacterienne, anticancerigene, antioxydante et immunomodulatrice et procede d'utilisation
AU2003202093A1 (en) Treatment of MS with goat serum
WO2003055518A1 (fr) Procede de traitement d'etats immuno-pathologiques et medicament correspondant
RU2192882C1 (ru) Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
WO2003055517A1 (fr) Procede de correction de la reponse immunitaire et medicament
JP2003514622A (ja) 患者中のサイトカインインヒビターを除去するための方法およびシステム
WO2003037372A1 (fr) Procede de retablissement de processus physiologiques perturbes et medicament
WO2003077946A1 (fr) Agent pharmaceutique et methode de traitement d'un syndrome pathologique associe a hemodyscrasia
WO2005004789A2 (fr) Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative ou quantitative de l'adn extracellulaire du sang
WO2004012765A1 (fr) Preparation medicinale et procede de traitement d'un syndrome pathologique determine par une perturbation de l'hematopoiese
CN110041404B (zh) 瓜氨酸化抗原修饰肽及其应用
RU2500427C2 (ru) Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
CN100518824C (zh) 重组人His-TT-B7-H1IgV肿瘤疫苗及其制备方法
CN114349857B (zh) 一种Treg细胞制备方法以及在自身免疫性疾病方面的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP